CorMedix Inc.
CorMedix Inc. is a U.S.-based biopharmaceutical company that develops and commercializes therapies for serious, life-threatening conditions. Its core commercial product is DefenCath, an antimicrobial catheter lock solution used in hemodialysis patients, and in 2025 the company expanded through the acquisition of Melinta Therapeutics, adding a hospital-focused infectious disease portfolio and a cardiovascular brand.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCommercial antimicrobial catheter lock solution sold in the U.S. dialysis market to reduce catheter-related bloodstream infections.
Hospital- and clinic-focused anti-infective products used for gram-positive, gram-negative, and fungal infections.
Branded cardiovascular product with mature, limited-demand sales in a highly genericized beta-blocker class.
BARDA and other licensing, milestone, royalty, and R&D service revenue tied to partnered programs.
Products
Reported · share of revenue- Defen Cath83.0 %
- Melinta Portfolio14.6 %
- Contract Revenue2.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
CorMedix sells primarily to U.S. dialysis organizations, outpatient service providers, specialty distributors, and hospital-system buyers that manage infection prevention and acute care treatment pathways. After the Melinta acquisition, its customer base also includes hospitals, emergency departments, outpatient clinics, and home infusion channels that purchase anti-infectives for serious infections.
Buy DefenCath to reduce catheter-related bloodstream infections in chronic hemodialysis patients.
Buy Melinta anti-infectives for inpatient and hospital-ecosystem treatment of serious infections.
Distribute product into outpatient and hospital channels and support access to end customers.
Fund BARDA-supported development programs for pediatric and biothreat indications.
Purchase TOPROL-XL where branded demand persists despite generic competition.
Strategy
CorMedix’s strategy is to maximize the value of its commercial portfolio by scaling DefenCath and using the Melinta platform to broaden hospital access and cross-selling opportunities. It is also pursuing label expansions for DefenCath and REZZAYO, while using business development to add assets that fit its sales infrastructure and support longer-term growth.
DefenCath is the largest contributor to net sales and the core growth driver.
The acquisition adds marketed products and a hospital-focused commercial platform.
Additional indications can extend product lifecycles and broaden reimbursement access.
New products can improve commercial leverage and reduce dependence on one asset.
Geography
CorMedix is primarily a U.S. business, with DefenCath commercialized in the United States and most customers located domestically. The Melinta acquisition adds U.S. hospital and clinic channels, while partnered licensing and BARDA-related activities extend some revenue exposure beyond pure product sales through collaboration and territory-based arrangements.
Risks
CorMedix is exposed to customer concentration, reimbursement changes, and dependence on third-party manufacturers, all of which can quickly affect revenue and margins. The company also faces typical biopharma risks around clinical development, regulatory approvals, competition, and supply chain reliability, with added sensitivity to cybersecurity and data/privacy compliance because operations rely on external vendors and digital systems.
- Reimbursement and pricing pressureImpact: HighLikelihood: High
DefenCath economics depend on dialysis reimbursement dynamics and payer acceptance.
Exposure: Transition from TDAPA to post-TDAPA add-on adjustment.
- Customer concentrationImpact: HighLikelihood: Medium
A few customers account for a large share of revenue and can change purchasing with little notice.
Exposure: Top three customers accounted for 79% of revenue in 2025.
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
The company outsources all manufacturing and relies on single-source suppliers for some inputs.
Exposure - Clinical and regulatory executionImpact: MediumLikelihood: Medium
Expanded indications require successful trials, filings, and FDA review.
Exposure: DefenCath CLABSI and REZZAYO prophylaxis programs.
- Cybersecurity and third-party vendor disruptionImpact: MediumLikelihood: Low
Operations depend on cloud, CRO, CMO, logistics, and analytics vendors.
Exposure
Accounting
Judgemental itemsProduct sales are recognized net of estimated discounts, rebates, returns, and chargebacks.
Impact: Can materially shift reported revenue and gross margin as estimates are updated.
The company must estimate product held by customers and short-dated/expired returns.
Impact: Affects net sales and accrual balances; accrued returns were significant in 2025.
Melinta acquisition accounting adds amortization of acquired product intangibles.
Impact: Raises cost of revenues and depresses operating profitability.
The Melinta transaction introduces fair value allocation and purchase accounting judgments.
Impact: Can affect future amortization, goodwill, and impairment risk.
The Berkeley Heights office lease creates ongoing right-of-use asset and liability accounting.
Impact: Affects operating lease expense and balance sheet obligations.
Similar listed companies
Publicly listed companies with a comparable business focus.
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Corcept Therapeutics Incorporated
CORT · Pharmaceutical Preparations
Corcept Therapeutics is a U.S.-based commercial-stage pharmaceutical company focused on medicines that modulate cortisol, with its core marketed product Korlym…
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
Corvex, Inc.
MOVE · Services-Computer Processing & Data Preparation
Korro Bio, Inc.
KRRO · Pharmaceutical Preparations
Biofrontera Inc.
BFRIW · Pharmaceutical Preparations
Last updated: 24/09/2026